SPACInsider Logo
Three SPAC IPOs on Deck to Price
by Kristi Marvin on 2018-11-13 at 3:05pm

Two SPACs are anticipated to price on Thursday, but there’s a chance we get all three.

It’s looks like we’re going to have a double header this week, since we’re hearing that Fintech III has moved their pricing to Thursday, alongside AMCI, which is already on the calendar for the same day. Plus, there’s the wildcard of Boxwood Merger Corp., which could make Thursday a hat-trick.

However, in light of the crowded schedule we thought it would be a good idea to summarize the terms for comparison:


Besides the obvious difference in the amount of warrants included in AMCI’s unit and AMCI’s life (18 months), both Boxwood and Fintech III look pretty similar as far as structure.  This leaves us to focus on the other key differences –  sector focus, team and to a lesser extent, underwriter.  However, regarding underwriter, it’s not as important at IPO as it is at combination.  To be clear, the underwriter’s capital markets skills are still important upfront, but they are crucial on the back end when trying to steer a deal through the completion process.  However, all of the above three deals have underwriters with solid names and SPAC experience – it’s a bit of a level underwriting playing field.

Nonetheless, even just evaluating sector focus is difficult because as we’ve seen, a SPAC can really combine with a company in any sector.  Just look at Hunter Maritime, which was an extremely focused shipping team that wound up presenting a deal with a Chinese fintech company.  They don’t call it a “blind pool” for nothing.  So ultimately, we’re left to focus on team.

Looking at the teams of all three of these IPOs, the Fintech team is the one with two successful SPACs under their belt – Fintech I, which combined with CardConnect (and was ultimately bought by First Data for $15.00 per share), and Fintech II, which combined with International Money Express (IMXI) and closed yesterday at $12.50.  As we’ve said, over and over, experience in SPACs counts. That’s not to say that AMCI and Boxwood can’t bring just as good deals, but it’s a lot easier to make a bet on a team with a track record and knows how to navigate the always challenging “de-SPACing” process.

So, which one is going to have the most demand at IPO?  Only the book-runners really true know what their demand looks like (and frankly, if you them asked them, every single one will tell you demand is HUUUUGE, regardless of whether it is or not), but it’s hard to argue with betting on the Fintech III team.  Two previously successful deals gives them the edge.

Lastly, regarding AMCI, this SPAC recently amended its terms. They went from 1/2 warrant to a full warrant and 24 months life to 18 months.  Those are costly changes to the SPAC management team and were needed to sweeten the deal.  So, are these changes to the terms enough to get investors clamoring for this SPAC or is the change itself a sign of investor apathy?  Well, we’ll know soon enough, but my bets on Fintech III as the SPAC to most likely trade well above $10.00 day-one.

Recent Posts
by Marlena Haddad on 2022-12-01 at 11:25am

  Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Latest SPAC News:  NYSE president says IPO proceeds fall more than 90% while Nasdaq president remains hopeful for 2023, and Giuliani brothers sell pharma stocks as they invest in biotech SPACs NYSE president says IPO proceeds fall...

by Marlena Haddad on 2022-12-01 at 10:02am

InterPrivate II Acquisition Corp. (NYSE:IPVA) disclosed this morning that it has restructured its bonus share agreement in connection to its proposed merger with carsharing marketplace Getaround. The parties previously agreed to reserve and set aside the bonus shares, consisting of 9,333,333 shares, to be allocated to the non-redeeming public stockholders, the designees of EarlyBirdCapital and the...

by Nicholas Alan Clayton on 2022-12-01 at 9:31am

Iris Acquisition Corp. (NASDAQ:IRAA) has entered into a definitive agreement to combine with biotech firm Liminatus at an enterprise value of $334 million. La Palma, California-based Liminatus is a clinical-stage drug developer working on a range of cancer treatments utilizing both preventative vaccines and CAR-T therapies. The combined company is expected to trade on the...

by Marlena Haddad on 2022-12-01 at 9:22am

Lakeshore Acquisition Corp. I (NASDAQ:LAAA) announced this morning that it has entered into a non-redemption agreement and amended its purchaser support agreement with initial shareholders in connection to its proposed merger with medical device company ProSomnus. The SPAC entered into non-redemption agreements with certain institutional investors for an aggregate of 200,339 shares of the purchaser. These investors...

by Nicholas Alan Clayton on 2022-11-30 at 6:01pm

The companies and sponsors of six SPAC deals are set to see their lock-ups expire before the end of the year. This is a relatively small monthly total as the wave of deals from 2020 and 2021 are still hitting this milestone. The list nonetheless includes some major names starting with Forafric (NASDAQ:AFRI), which is...

Privacy Policy|Terms Of Use
Copyright © 2022 SPACInsider, Inc. All Rights Reserved